

Short Communication



Adverse Blood Transfusion Reactions in Patients on Haemodialysis

Akhlaaq Wazeer^{1,2}, Shahzaib Raza^{1,2}, Usama Qamar³

¹Mirpur Regional Blood Centre, Divisional Headquarters Teaching Hospital, State Ministry of Health, AJK, Pakistan

²Department of Allied Health Sciences, Mirpur Institute of Medical Sciences, Mirpur, AJK, Pakistan

³Department of Pathology and Blood Bank, Dr. Akbar Niazi Teaching Hospital, Islamabad, Pakistan

Address of Correspondent

Akhlaaq Wazeer

Mirpur Regional Blood Centre
Divisional Headquarters Teaching Hospital
State Ministry of Health, AJK, Pakistan
E: akhlaaqwazeer@gmail.com

Cite this article as: Wazeer A, Raza S, Qamar U. Adverse Blood Transfusion Reactions in Patients on Haemodialysis. Ann Pak Inst Med Sci. 2024;20(Suppl. 2):867-869. doi: 10.48036/apims.v20iSuppl.2.1284.

Blood transfusions are a critical aspect of managing patients undergoing haemodialysis, especially for those with chronic kidney disease (CKD).¹ CKD patients often suffer from anaemia due to reduced erythropoietin production by the kidneys. When erythropoiesis-stimulating agents and iron supplements fail to adequately increase haemoglobin levels, blood transfusions become necessary to prevent severe anaemia and associated complications. Although effective, transfusions come with risks such as iron overload, immune sensitization, and transmission of infections.² Careful consideration of the indications, close monitoring, and the judicious use of transfusions are essential to optimize patient outcomes while minimizing potential adverse effects in haemodialysis settings.

Haemodialysis patients often experience anaemia as a result of chronic kidney disease (CKD), leading to a frequent need for blood transfusions.³ Despite the efficacy of blood transfusions in managing anaemia, they are associated with several adverse reactions, some of which can pose significant risks to the already vulnerable population of dialysis patients.⁴ Adverse transfusion reactions, including both immunologic and non-immunological complications, can intensify existing health issues, potentially leading to outcomes like acute kidney injury (AKI) and other major adverse kidney events (MAKE).⁵

The physiological strain from managing immune or inflammatory responses associated with transfusion

reactions can impair renal function. In a recent study, transfusion reactions increased the likelihood of developing AKI by twofold, especially among patients with comorbid conditions such as diabetes and cardiovascular disease.⁶ In addition, MAKE, including a decline in glomerular filtration rate (GFR) and increased mortality, was more common in patients who experienced transfusion reactions, underscoring the long-term renal risks associated with these reactions.

As stated above, haemodialysis patients often require transfusions due to inadequate erythropoietin production by the diseased kidneys, which leads to chronic anaemia. While erythropoiesis-stimulating agents (ESAs) have reduced the frequency of transfusions, some patients still require red blood cell (RBC) transfusions, particularly those who exhibit ESA resistance or have contraindications to ESA therapy.⁷ Additionally, certain clinical situations, such as severe symptomatic anaemia, demand rapid intervention through transfusions.

Despite the benefits, blood transfusions present a unique set of risks for dialysis patients, including increased risk of alloimmunization, which complicates future kidney transplant eligibility.⁸ Alloimmunization occurs when the patient develops antibodies against foreign antigens in transfused blood, potentially leading to future transfusion complications and limiting the patient's compatibility with donor organs.

Adverse transfusion reactions can be categorized into infectious and non-infectious complications. These

include febrile non-haemolytic transfusion reactions (FNHTR), allergic reactions, transfusion-associated circulatory overload (TACO), transfusion-related acute lung injury (TRALI), and haemolytic transfusion reactions. Studies have shown that FNHTR and allergic reactions are the most common. FNHTR is characterized by a mild fever and chills during or shortly after transfusion, resulting from an immune response to leukocytes or cytokines in transfused blood.⁹ TACO and TRALI, though less common, are critical complications that require immediate medical attention, as they can lead to respiratory distress and life-threatening pulmonary complications.¹⁰ TACO occurs when rapid transfusion leads to fluid overload, overwhelming the patient's cardiovascular system, and is especially risky in dialysis patients who already struggle with fluid management. TRALI, on the other hand, is a rare but severe reaction characterized by non-cardiogenic pulmonary edema, often resulting from an immune response to antibodies in the donor blood that interact with the recipient's white blood cells.¹¹

Infectious risks, though minimized through rigorous screening and haemovigilance programmes, are still present, particularly bacterial and parasitic infections. The risk of infection is higher in patients receiving multiple transfusions due to increased exposure to blood components.¹² This risk is magnified in dialysis patients, as vascular access used during haemodialysis can serve as an entry point for pathogens, increasing the likelihood of bacteremia and subsequent complications.¹³

To minimize the risk of adverse transfusion reactions, several strategies can be employed. Preventive measures include using leukoreduced blood products, which help reduce the risk of FNHTR and alloimmunization by removing leukocytes from the blood product.¹⁴ The use of leukoreduced PRBCs is particularly beneficial for haemodialysis patients, who are often immunocompromised and more susceptible to transfusion reactions.

Transfusion decisions in dialysis patients should be based on a careful risk-benefit assessment, considering factors such as symptom severity, haemoglobin levels, and the potential risks associated with ESA therapy.¹⁵ For patients who are eligible for kidney transplantation, transfusions are often avoided, if possible, to minimize alloimmunization risk, as developing antibodies against donor antigens can significantly reduce transplant compatibility.¹⁶

Another critical aspect of managing transfusion reactions is close monitoring during and after transfusion. Vital signs should be continuously monitored, and any signs of adverse reactions, such as fever, dyspnoea, or hypotension, should prompt immediate intervention. For patients with a history of severe transfusion reactions, premedication with antihistamines or corticosteroids may reduce the likelihood of future reactions.¹⁷

Adverse blood transfusion reactions in haemodialysis patients are a significant clinical concern, necessitating a careful approach to blood transfusion management. Enhanced haemovigilance programmes and preventive measures, including leukoreduction and judicious transfusion practices, play a pivotal role in minimizing these risks.

References

1. Lawler EV, Bradbury BD, Fonda JR, Gaziano JM, Gagnon DR. Transfusion burden among patients with chronic kidney disease and anemia. *Clin J Am Soc Nephrol*. 2010;5(4):667-72. <https://doi.org/10.2215/CJN.06020809>.
2. Lawler EV, Gagnon DR, Fink J, Seliger S, Fonda J, Do TP, Gaziano JM, Bradbury BD. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration. *Nephrol Dial Transplant*. 2010;25(7):2237-44. <https://doi.org/10.1093/ndt/gfp758>.
3. Mikhail A, Brown C, Williams JA, Mathrani V, Shrivastava R, Evans J, Isaac H, Bhandari S. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. *BMC Nephrol*. 2017;18(1):345. <https://doi.org/10.1186/s12882-017-0688-1>.
4. Kooshki A, Akbarzadeh R, Amin B, Tofiqhiyan T, Foroumandi E. Synbiotic supplement for treatment of iron deficiency anaemia in haemodialysis patients: A randomized controlled trial. *Nephrology (Carlton)*. 2023;28(4):234-239. <https://doi.org/10.1111/nep.14149>.
5. Patidar KR, Naved MA, Kabir S, Grama A, Allegretti AS, Cullaro G, Asrani SK, Worden A, Desai AP, Ghabril MS, Nephew LD, Orman ES. Longer time to recovery from acute kidney injury is associated with major adverse kidney events in patients with cirrhosis. *Aliment Pharmacol Ther*. 2023;57(12):1397-1406. <https://doi.org/10.1111/apt.17457>.
6. De La Vega-Méndez FM, Estrada MI, Zuno-Reyes EE, Gutierrez-Rivera CA, Oliva-Martinez AE, Díaz-Villavicencio B, et al. Blood transfusion reactions and risk of acute kidney injury and major adverse kidney events. *J Nephrol*. 2024;37(4):951-960. <https://doi.org/10.1007/s40620-023-01859-7>.

7. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. *Cochrane Database Syst Rev.* 2014;2014(12):CD010590. <https://doi.org/10.1002/14651858.CD010590.pub2>.
8. Yusoff SM, Bahar R, Hassan MN, Noor NHM, Ramli M, Shafii NF. Prevalence of Red Blood Cell Alloimmunization among Transfused Chronic Kidney Disease Patients in Hospital Universiti Sains Malaysia. *Oman Med J.* 2020;35(5):e177. <https://doi.org/10.5001/omj.2020.95>.
9. Wang H, Ren D, Sun H, Liu J. Research progress on febrile non-hemolytic transfusion reaction: a narrative review. *Ann Transl Med.* 2022;10(24):1401. <https://doi.org/10.21037/atm-22-4932>.
10. Roubinian N. TACO and TRALI: biology, risk factors, and prevention strategies. *Hematology Am Soc Hematol Educ Program.* 2018;2018(1):585-594. <https://doi.org/10.1182/asheducation-2018.1.585>.
11. Toy P, Lowell C. TRALI--definition, mechanisms, incidence and clinical relevance. *Best Pract Res Clin Anaesthesiol.* 2007;21(2):183-93. <https://doi.org/10.1016/j.bpa.2007.01.003>.
12. Singh G, Sehgal R. Transfusion-transmitted parasitic infections. *Asian J Transfus Sci.* 2010;4(2):73-7. <https://doi.org/10.4103/0973-6247.67018>.
13. Shahcheraghi S H, Ayatollahi J, Darabi Mohebbi M. Important Bacterial and Viral Infections in Patients with Hemodialysis. *Int J Infect.* 2017;4(2):e40217. <https://doi.org/10.5812/iji.40217>
14. Waheed U, Wazeer A, Khan R, N Saba N, Qasim Z. Effectiveness of leucodepletion filters in reducing adverse transfusion reactions in multi-transfused beta thalassaemia major patients. *Vox Sanguinis* 2024; 119 (Suppl. S1): p 538. <https://doi.org/10.1111/vox.13650>.
15. Whitman CB, Shreay S, Gitlin M, van Oijen MG, Spiegel BM. Clinical factors and the decision to transfuse chronic dialysis patients. *Clin J Am Soc Nephrol.* 2013;8(11):1942-51. <https://doi.org/10.2215/CJN.00160113>.
16. Hassan S, Mumford L, Robinson S, Foukanelli D, Torpey N, Ploeg RJ, Mamode N, Murphy MF, Brown C, Roberts DJ, Regan F, Willicombe M. Blood transfusions post kidney transplantation are associated with inferior allograft and patient survival-it is time for rigorous patient blood management. *Front Nephrol.* 2023;3:1236520. <https://doi.org/10.3389/fneph.2023.1236520>.
17. Wong-Sefdan I, Ale-Ali A, DeMoor PA, Martinez S, Curtin P, Lane T, Roeland E. Implementing inpatient, evidence-based, antihistamine-transfusion premedication guidelines at a single academic US hospital. *J Community Support Oncol.* 2014;12(2):56-64. <https://doi.org/10.12788/jcsco.0016>.